Ancor Capital Partners has acquired WellSpring Pharmaceutical, based in Sarasota, FL, and Toronto, ON. WellSpring manufactures and markets specialty prescription and OTC products in North America and also offers contract manufacturing through its production plant in Ontario. Ancor partnered with Sentinel Capital and Yukon Capital to complete the transaction. Financial terms were not disclosed.

“WellSpring represents the 15th acquisition of a healthcare company for Ancor and combines our experience in contract manufacturing, pharmaceutical sales and OTC products. We are very pleased to have teamed with Sentinel and Yukon on this acquisition,” said J. Randall Keene, managing partner at Ancor Capital Partners.

“WellSpring is an innovator that provides quality pharmaceutical products and related services across a diverse set of end markets. The opportunity to invest alongside Ancor was also a strong incentive for us,” said Eric D. Bommer, partner at Sentinel. “We believe WellSpring is well positioned to accelerate its growth, and we look forward to working with its management team and Ancor in taking WellSpring to the next level.”

Dr. Robert A. Vukovich, WellSpring’s founder, president and chief executive officer, reinvested in the business and will remain on the company’s board of directors. Also, Bonnie Feeney, president and chief operating officer of WellSpring Canada and Wendy Shusko, chief financial officer and chief operating officer of WellSpring USA, have reinvested in the transaction and both will continue as a part WellSpring’s senior management team.

“Under our new ownership with Ancor and Sentinel, we believe we can achieve the aggressive growth opportunities in the market and deliver medicines and products of the highest quality to those who need them,” said Ms. Shusko.

Ms. Feeney commented, “This transaction allows us to continue to utilize our state-of-the-art manufacturing facility in Canada through a new phase of growth.”